86 related articles for article (PubMed ID: 1991496)
1. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood.
Gianni AM; Siena S; Bregni M
Exp Hematol; 1991 Feb; 19(2):147-8. PubMed ID: 1991496
[No Abstract] [Full Text] [Related]
2. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic precursor cell exhaustion is a cause of proliferative defect in primitive hematopoietic stem cells (PHSC) after chemotherapy.
Gardner RV; Astle CM; Harrison DE
Exp Hematol; 1997 Jun; 25(6):495-501. PubMed ID: 9197327
[TBL] [Abstract][Full Text] [Related]
4. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors.
Siena S; Bregni M; Bonsi L; Sklenar I; Bagnara GP; Bonadonna G; Gianni AM
Exp Hematol; 1993 Nov; 21(12):1583-90. PubMed ID: 7691640
[TBL] [Abstract][Full Text] [Related]
5. [Study of biologic properties of hemopoietic stem cells in peripheral blood of mice].
Xu HR
Zhonghua Zhong Liu Za Zhi; 1982 Aug; 4(3):165-7. PubMed ID: 7173019
[No Abstract] [Full Text] [Related]
6. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
[TBL] [Abstract][Full Text] [Related]
7. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.
Weaver CH; Schwartzberg LS; Birch R; Greco FA; Hainsworth J; Drapkin R; Campos L; Grapski R; Schwerkoske J; Lautersztain J; Hazelton B; Schnell F; Babcock W; Buckner CD
Biol Blood Marrow Transplant; 1997 Jun; 3(2):83-90. PubMed ID: 9267668
[TBL] [Abstract][Full Text] [Related]
8. [B-lymphocytes and the proliferative response of a hemopoietic stem cell to antigenic action].
Kozlov VA; Tsyrlova IG; Gaĭdul' KV
Dokl Akad Nauk SSSR; 1986; 286(1):239-41. PubMed ID: 3485040
[No Abstract] [Full Text] [Related]
9. Proceedings: Studies on hemopoietic stem cell kinetics after a single high dose of actinomycin D (AM), cyclophosphamide (CY) and busulphan (BS) in the mouse.
Scaro JL; Barrio Rendo ME; Buys MC; Zenteno A
Acta Physiol Lat Am; 1973; 23(6):548-50. PubMed ID: 4795053
[No Abstract] [Full Text] [Related]
10. Mobilization of peripheral blood stem cells: comparing cyclophosphamide and growth factor based regimens.
Janssen WE; Smilee R; Carter R; Rahn D; Cairo M; Hiemenz JH; Zorsky PE; Fields KK; Ballester O; Perkins J
Prog Clin Biol Res; 1994; 389():429-39. PubMed ID: 7700915
[No Abstract] [Full Text] [Related]
11. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide.
Douay L; Giarratana MC; Labopin M; Bardinet D; Bouchet S; Gorin NC
Bone Marrow Transplant; 1995 May; 15(5):769-75. PubMed ID: 7670404
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide-induced alterations of bone marrow endothelium: implications in homing of marrow cells after transplantation.
Shirota T; Tavassoli M
Exp Hematol; 1991 Jun; 19(5):369-73. PubMed ID: 2026187
[TBL] [Abstract][Full Text] [Related]
13. [Efficiency of high-dose FEC chemotherapy for the mobilization of hematopoietic stem cells into peripheral blood].
D'Hondt L; André M; Canon JL; Guillaume T; Doyen C; Feyens AM; Chatelain B; Dromelet A; Humblet Y; Longueville J; Symann M
Bull Cancer; 1997 Jul; 84(7):729-33. PubMed ID: 9339199
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro effects of cyclophosphamide derivatives on murine bone marrow-derived stromal and hemopoietic progenitor cell classes.
de Jong JP; Nikkels PG; Brockbank KG; Ploemacher RE; Voerman JS
Cancer Res; 1985 Sep; 45(9):4001-5. PubMed ID: 3896474
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s).
Siena S; Bregni M; Bonsi L; Strippoli P; Peccatori F; Magni M; Di Nicola M; Bagnara GP; Massimo Gianni A
Stem Cells; 1993 Jul; 11 Suppl 2():72-5. PubMed ID: 8104618
[TBL] [Abstract][Full Text] [Related]
16. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte-colony stimulating factor impedes recovery from damage caused by cytotoxic agents through increased differentiation at the expense of self-renewal.
van Os R; Robinson S; Sheridan T; Mauch PM
Stem Cells; 2000; 18(2):120-7. PubMed ID: 10742384
[TBL] [Abstract][Full Text] [Related]
18. Effect of H2 antagonists cimetidine and famotidine on the hemotoxicity of cyclophosphamide.
Lerza RA; Bogliolo GV; Mencoboni MP; Saviane AG; Pannacciulli IM
Anticancer Res; 1988; 8(6):1241-5. PubMed ID: 2905881
[TBL] [Abstract][Full Text] [Related]
19. The effect of cyclophosphamide on hematopoietic stem cells.
Fried W; Johnson C
Radiat Res; 1968 Dec; 36(3):521-7. PubMed ID: 17387883
[TBL] [Abstract][Full Text] [Related]
20. The elusive peripheral blood hemopoietic stem cell.
Hogge DE; Sutherland HJ; Lansdorp PM; Phillips GL; Eaves CJ
Semin Hematol; 1993 Oct; 30(4 Suppl 4):82-9; discussion 90-1. PubMed ID: 7905666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
